卵巢透明细胞癌中的血清 microRNAs。

Serum microRNAs in clear cell carcinoma of the ovary.

机构信息

Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Gynecologic Cancer Research Centre, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan; Department of Biomedical Science, School of Medicine, Chang Gung University, Taoyuan, Taiwan.

出版信息

Taiwan J Obstet Gynecol. 2014 Dec;53(4):536-41. doi: 10.1016/j.tjog.2014.07.005.

DOI:10.1016/j.tjog.2014.07.005

PMID:25510697

Abstract

OBJECTIVE

To identify candidate microRNAs (miRNAs) in the serum of patients with clear cell carcinomas in monitoring disease progression.

MATERIALS AND METHODS

The sera of patients with diagnosed ovarian clear cell carcinoma were collected from 2009 to 2012. Real-time quantitative polymerase chain reaction (PCR) analysis for 270 miRNAs was performed. To offset the potential extraction bias, an equal amount of Caenorhabditis elegans cel-miR-238 was added to each serum specimen before miRNA isolation. miRNA expression was analyzed using the ΔCt method, with cel-miR-238 as controls.

RESULTS

Twenty-one patients with clear cell carcinoma were included. In the discovery phase on four pairs of pre- and postoperative sera, 18 differentially expressed miRNAs were selected from 270 miRNAs. In the validation phase on an independent set of 11 pairs of pre- and postoperative sera, 4 miRNAs (hsa-miR-130a, hsa-miR-138, hsa-miR-187, and hsa-miR-202) were confirmed to be higher in the preoperative sera. In the application phase, hsa-miR-130a remained consistent with the different time points in seven of the 10 patients during clinical follow-up periods. More importantly, in three patients, hsa-miR-130a levels were elevated in early disease recurrences before CA125 was found to be elevated.

CONCLUSION

Hsa-miR-130a may be a useful serum biomarker for detecting recurrence of ovarian clear cell cancer, and warrants further studies.

摘要

目的

在监测疾病进展中，鉴定卵巢透明细胞癌患者血清中的候选 microRNAs（miRNAs）。

材料与方法

收集 2009 年至 2012 年间确诊的卵巢透明细胞癌患者的血清。对 270 个 miRNA 进行实时定量聚合酶链反应（PCR）分析。为了抵消潜在的提取偏差，在 miRNA 分离之前，将等量的秀丽隐杆线虫 cel-miR-238 添加到每个血清标本中。使用 cel-miR-238 作为对照，通过 ΔCt 方法分析 miRNA 表达。

结果

共纳入 21 名透明细胞癌患者。在 4 对术前和术后血清的发现阶段，从 270 个 miRNA 中选择了 18 个差异表达的 miRNA。在 11 对独立的术前和术后血清的验证阶段，有 4 个 miRNA（hsa-miR-130a、hsa-miR-138、hsa-miR-187 和 hsa-miR-202）在术前血清中表达较高。在应用阶段，在 10 名患者的 7 名患者的临床随访期间，hsa-miR-130a 与不同时间点保持一致。更重要的是，在 3 名患者中，在 CA125 升高之前，hsa-miR-130a 水平在早期疾病复发时升高。